NCT01777594View on ClinicalTrials.gov

Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
DRUG

G-202

G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity

Trial Locations (4)

75230

Mary Crowley Cancer Research Center, Dallas

77030

Oncology Consultants, PA, Houston

University of Texas Health Sciences Center at Houston, Memorial Hermann Cancer Center, Houston

78229-3900

The University of Texas Health Science Center at San Antonio, San Antonio

Sponsors

Lead Sponsor

GenSpera, Inc.
All Listed Sponsors
lead

GenSpera, Inc.

INDUSTRY